Logo

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

Share this

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

Shots:

  • Lilly to receive up front- milestones- as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China
  • SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China- Hong Kong- Macau- And Taiwan
  • Alpha-synuclein directed therapies help to treat patients with Parkinson’s disease and related neurological disorders addressing the unmet medical need

  Ref: Business Wire | Image: Eli Lilly 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions